Please replace the paragraph beginning at page 2, line 26, with the following rewritten paragraph:

--In accordance with a further embodiment, the invention pertains to the use of compounds of formula (I) and/or their pharmaceutically acceptable salts for therapeutic treatment of neuropathies of the type mentioned above.--

Please delete the paragraph beginning at page 2, line 29.

IN THE CLAIMS:

Please change "Patent claims" to --What is Claimed--.

Please cancel claim 4, without prejudice.

Please amend claims 1-3, and 5, as follows:

1. (Amended) A pharmaceutical agent for treatment of neuropathies, comprising a compound of formula (I):



(I)

in which:

R^1 = C_{1-6}alkyl, optionally substituted with halogen,

R^2 = hydrogen or C_{1-4}alkyl, optionally substituted by halogen or replaced with halogen,

R^3 = C_{2-4}alkyl, optionally substituted with halogen,

R^4 = $SO_2NR^5R^6$,

C_{1-4}alkyl, optionally substituted with NR^5R^6,

CN, $CONR^5R^6$, CO_2R^7, or halogen,

C_{2-4}-alkenyl, possibly substituted with

NR^5R^6, $SONR^5R^6$, $CONR^5R^6$, CO_2R^7, or halogen,

C_{2-4}-alkanoyl, optionally substituted with

NR^5R^6, $SONR^5R^6$, $CONR^5R^6$, CO_2R^7, or halogen,

R^5 and R^6, independent of one another, represent hydrogen or C_{1-4}alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR^8)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C_{1-4}alkyl groups,

R^7 = hydrogen, C_{1-4}alkyl, optionally, are substituted with fluorine, and

R^8 = hydrogen, C_{1-3}alkyl, or hydroxy alkyl with 1 - 4 C atoms; or of a pharmaceutically acceptable salt of such a compound.

2. (Amended) The pharmaceutical agent according to Claim 1, comprising a compound of formula (Ia):



(Ia)

in which the groups R^1 to R^3 have the meaning specified in Claim 1, and R^9 is an alkyl group having 1 - 4 C atoms which, optionally, are substituted or replaced by halogen; or of a pharmaceutically acceptable salt of such a compound.

3. (Amended) The pharmaceutical agent according to Claim 1, comprising a compound of formula (III):



(III)

or of a pharmaceutically acceptable salt of such a compound.

5. (Amended) A chemotherapeutic method for treatment of neuropathies characterized by application to a patient of a pharmaceutical agent comprising a compound of formula (I):



(I)

in which

R^1 = C_{1-6}alkyl, optionally substituted with halogen,

R^2 = hydrogen or C_{1-4}alkyl, optionally substituted with halogen or replaced with halogen,

R^3 = C_{2-4}alkyl, optionally substituted with halogen,

R^4 = $SO_2NR^5R^6$,

C_{1-4}alkyl, optionally substituted with NR^5R^6,

CN, $CONR^5R^6$, CO_2R^7, or halogen,

C_{2-4}-alkenyl, optionally substituted with

NR^5R^6, $SONR^5R^6$, $CONR^5R^6$, CO_2R^7, or halogen,

C_{2-4}-alkanoyl, optionally substituted with

NR^5R^6, $SONR^5R^6$, $CONR^5R^6$, CO_2R^7, or halogen,

R^5 and R^6, independent of one another, represent hydrogen or C_{1-4}alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR^8)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C_{1-4}alkyl groups,

R^7 = hydrogen or C_{1-4}alkyl, optionally, substituted with fluorine, and

R^8 = hydrogen, C_{1-3}alkyl, or hydroxy alkyl having 1 - 4 C atoms, or of a pharmaceutically acceptable salt of such a compound.

Please add the following new claims 6, 7 and 8.

6. (New) --The method of claim 5, wherein from 1-100 mg/day of said pharmaceutical agent is administered to a patient being treated.

7. (New) The method of claim 5, wherein from 5-50 mg/day of said pharmaceutical agent is administered to a patient being treated.

8. (New) The method of claim 5, wherein from 25-50 mg/day of said pharmaceutical agent is administered to a patient being treated.--